Clinical trial Recruiting at 1 site Observational Ages 5 to 75

Understanding COVID-19 transmission and health impacts in Malawi

Official title: COVID-19 Transmission and Morbidity in Malawi

Run by Boston University · NCT05973084 · Data updated 2026-11-12

This study is trying to understand why COVID-19 seems to affect people in Malawi less severely by looking at factors like immune responses and other health conditions in those who have the virus and their close contacts.

More SARS CoV 2 Infection trials

Quick facts

Study typeObservational
Ages5 Years to 75 Years
SexAll
Enrollment1500 (estimated)
SponsorBoston University
Academic / other
Locations2 sites (Boston, Massachusetts and 1 other locations)
StatusRecruiting
StartedJanuary 17, 2023
Main results expectedMarch 2028
Study endsMarch 2028
Registry record updatedMay 28, 2026
Trial IDNCT05973084 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals aged 5 to 75 years with confirmed COVID-19 symptoms living in Blantyre, Malawi, and their household contacts.

Probably not a fit

Patients who have received a SARS-CoV-2 vaccine in the previous 3 months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the unique factors contributing to lower COVID-19 morbidity and mortality rates in Malawi compared to other regions. It will enroll symptomatic individuals with confirmed SARS-CoV-2 infections, their household contacts, and vaccinated individuals to assess the role of innate immune responses, malaria, and intestinal parasites in influencing susceptibility to infection and vaccine responses. Participants will be followed for up to 1.5 years to evaluate antibody responses and memory B cell longevity.

Why it matters

Potential benefit: If successful, this study could provide insights into protective immune factors that may inform COVID-19 prevention and treatment strategies in similar populations.

How similar studies have gone: While there have been studies on COVID-19 transmission and immunity, this specific focus on the interplay of malaria, intestinal parasites, and innate immunity in a sub-Saharan context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria Index Cases

1. Presents with symptoms of COVID-19 and has infection confirmed through RT-PCR or a rapid antigen test;
2. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers for the following 6 months;
3. Confirmed SARS-CoV-2 infection and share a household with 1 or more individuals of eligible age;
4. Has not received a SARS-CoV-2 vaccine in the previous 3 months
5. Willingness to comply with study procedures and visits, and provides informed consent.

Household Contacts of the Confirmed SARS-CoV-2 Case

1. Aged 5 years to 75 years and plans to live in Blantyre, in the catchment area of the target research health centers in the following 6 months;
2. Willingness to comply with study procedures and follow-up visits and provides informed consent.
3. Has not received a SARS-CoV-2 vaccine in the previous 3 months

Vaccinees

1\) Aged 18 years to 75 years; 2) Willingness to receive the primary regimen of the AZ and/or JJ vaccines 2) Not in the other 2 cohorts; 4) Willingness to comply with study procedures and follow-up visits and provides informed consent.

5\) Has not received a prior dose of a SARS-CoV-2 vaccine

Exclusion Criteria Index Cases

1. Conditions that precludes from adherence to the visit schedule;
2. 50% or more of household members decline to participate.
3. Pregnancy at the enrollment visit
4. Long term use of cotrimoxazole prophylaxis

Household Contacts of the Confirmed SARS-CoV-2 Case

1. Conditions that preclude adherence to the visit schedule.
2. Participants with 2 consecutive negative SARS-CoV-2 RT-PCRs will be excluded from visits after M1.
3. Pregnancy at the enrollment visit
4. Long term use of cotrimoxazole prophylaxis

Vaccinees

1. Conditions that preclude adherence to the visit schedule.
2. Pregnancy at the enrollment visit
3. Long term use of cotrimoxazole prophylaxis

Where it's running

  • Health center
    Blantyre, Malawi
    Recruiting
  • BU School of Public Health, Global Health Department
    Boston, Massachusetts, United States
    Active not recruiting

Study contacts

  • Principal investigator: Clarissa Valim, MD ScD — BU School of Public Health, Department of Global Health
  • Study coordinator: Clarissa Valim, MD ScD
  • Email: cvalim@bu.edu
  • Phone: (617) 414-1260

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Cardiovascular health five years after MIS-C in children

    This study tests whether kids who had MIS-C still show cardiovascular differences five years later compared with healthy peers.

    Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07659847

  • Remdesivir to prevent severe COVID-19 in kidney transplant patients

    This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.

    Recruiting Phase 2 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Badalona, Barcelona · NCT07197164

  • 2-HOBA to reduce persistent immune activation in Long COVID with POTS

    This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.

    Recruiting Phase 2 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07189936

  • TFH-targeting COVID-19 booster vaccines with and without the 's3' component

    This trial will test two experimental COVID-19 booster vaccines — one with an added 's3' component and one without — in healthy adults 40–64 to see if 's3' makes immune responses bigger, broader, and longer-lasting and to check safety.

    Recruiting at 2 sites Phase 1/2 University of California, Los Angeles · Los Angeles, California and 1 other locations · NCT06810934

  • Evaluating Baricitinib for Long COVID Symptoms

    This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.

    Recruiting at 17 sites Phase 3 Vanderbilt University Medical Center · Tucson, Arizona and 16 other locations · NCT06631287

  • Study on influenza and COVID-19 effects in pregnant women in India

    This study is testing how getting both COVID-19 and influenza affects pregnant women and their babies, while also looking at how vaccinations might help reduce risks during pregnancy.

    Recruiting at 2 sites Boston University · Boston, Massachusetts and 1 other locations · NCT06168019

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.